Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Eitemau Tebyg

• Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)
  gan: Clement, P. M., et al.
  Cyhoeddwyd: (2016)
• Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
  gan: Guo, Y, et al.
  Cyhoeddwyd: (2019)
• Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
  gan: Cohen, E. E. W., et al.
  Cyhoeddwyd: (2017)
• Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
  gan: Young, Natalie R., et al.
  Cyhoeddwyd: (2015)
• Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
  gan: Argiris, Athanassios, et al.
  Cyhoeddwyd: (2017)